ATRenew to Report Third Quarter 2024 Financial Results on November 20, 2024
SHANGHAI, Nov. 6, 2024 /PRNewswire/ — ATRenew Inc. (“ATRenew” or the “Company”) (NYSE: RERE), a leading technology-driven pre-owned... Read more.
Groupe Mutuel integrates Ada Health’s AI-powered care navigation into their member experience across Switzerland to support personalized, streamlined access to care
Ada Health’s AI health assessment and care navigation technology is integrated into Groupe Mutuel’s app. It helps members better understand their symptoms... Read more.
GTN bolsters European growth with FCA authorisation
LONDON, Nov. 6, 2024 /PRNewswire/ — GTN, a global fintech redefining investing and trading for all, is proud to announce that it has secured authorisation... Read more.
ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing,... Read more.
ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing,... Read more.
AMPCO METAL Acquires Schmelzmetall Group to Expand Capabilities and Enhance Customer Offerings
MARLY, Switzerland, Nov. 6, 2024 /PRNewswire/ — AMPCO METAL, a global leader in copper-based alloys, is pleased to announce its acquisition of Switzerland-based... Read more.
AMPCO METAL Acquires Schmelzmetall Group to Expand Capabilities and Enhance Customer Offerings
MARLY, Switzerland, Nov. 6, 2024 /PRNewswire/ — AMPCO METAL, a global leader in copper-based alloys, is pleased to announce its acquisition of Switzerland-based... Read more.
Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma
NANJING, China, Nov. 6, 2024 /PRNewswire/ — On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced... Read more.
Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma
NANJING, China, Nov. 6, 2024 /PRNewswire/ — On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced... Read more.
October 2024 Global Sources Hong Kong Shows Conclude, Innovation Drives New Trends in Global Trade, Multiple Shows Combine to Boost Global Trade Development
HONG KONG, Nov. 6, 2024 /PRNewswire/ — The October 2024 Global Sources Hong Kong Shows at AsiaWorld-Expo have concluded recently. The three-phase show program,... Read more.